<DOC>
	<DOCNO>NCT02111564</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety rivaroxaban compare placebo prevention symptomatic venous thromboembolism ( VTE ) event VTE-related death post-hospital discharge high-risk , medically ill patient .</brief_summary>
	<brief_title>A Study Rivaroxaban ( JNJ-39039039 ) Venous Thromboembolic Risk Post-Hospital Discharge Patients</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician participant know identity assign treatment ) , placebo ( inactive substance compare drug test whether drug real effect ) -controlled , event-driven , multicenter study patient hospitalize specific acute medical illness risk factor venous thromboembolism ( VTE ) . The study design evaluate rivaroxaban prevention symptomatic VTE event VTE-related death period 45 day post-hospital discharge . The study consist screen phase , 45-day double-blind treatment phase , 30-day follow-up phase . Study drug start randomization ( Day 1 ) , continue Day 45 ( inclusive ) . A total approximately 8,000 patient randomly assign either rivaroxaban placebo 1:1 ratio . The total duration patient complete study randomization expect 75 day .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Pulmonary Valve Insufficiency</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Key The duration index hospitalization must least 3 10 consecutive day Must meet venous thromboembolism ( VTE ) risk criterion total modify Improve VTE Risk Score : great equal 4 , 3 Ddimer &gt; 2* upper limit normal ( ULN ) , 2 Ddimer &gt; 2*ULN Key Any serious bleeding within 3 month prior randomization occur index hospitalization Serious trauma ( include head trauma ) within 4 week randomization History hemorrhagic stroke time past Any medical condition require chronic use parenteral oral anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Respiratory Insufficiency</keyword>
	<keyword>Stroke Acute</keyword>
	<keyword>Infectious Diseases</keyword>
	<keyword>Rheumatic Diseases</keyword>
	<keyword>Medically ill Patient</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Prophylactic Anti-Coagulation</keyword>
</DOC>